Background
Materials and methods
Literature search
Study selection and data extraction
Quality assessment
Statistical analysis
Results
Identification of the included studies
Association of MALAT1 with clinicopathological parameters
Clinicopathological parameters | Studies (n) | Patient s (n) | OR (95% CI) | P | Heterogeneity (I2, P) | Model |
---|---|---|---|---|---|---|
Age (elderly vs. nonelderly) | 33 | 3127 | 0.983 (0.848–1.140) | 0.823 | 0.0%, 0.991 | Fixed |
Gender (female vs. male) | 28 | 2459 | 0.860 (0.726–1.018) | 0.080 | 12.6%, 0.275 | Fixed |
Tumor size (large size vs. small size) | 19 | 1811 | 1.875 (1.257–2.795) | 0.002 | 72.8%, 0.000 | Random |
Lymph node metastasis (positive vs. negative) | 26 | 2440 | 2.335 (1.606–3.395) | 0.000 | 72.7%, 0.000 | Random |
Distant metastasis (presence vs. absence) | 16 | 1514 | 2.456 (1.407–4.286) | 0.002 | 69.9%, 0.000 | Random |
Differentiation (poor vs. well, moderate) | 21 | 1980 | 1.112 (0.916–1.351) | 0.284 | 49.6%, 0.005 | Fixed |
TNM stage (III + IV vs. I + II) | 11 | 1083 | 2.034 (1.111–3.724) | 0.021 | 77.7%, 0.000 | Random |
Association of MALAT1 with survival outcomes
Survival analysis | Subgroup | Studies (n) | Patients (n) | HR (95% CI) | P | Heterogeneity (I2, P) |
---|---|---|---|---|---|---|
Univariate | Overall | 15 | 1869 | 2.296 (1.716–3.072) | 0.000 | 67.6%, 0.000 |
Region | ||||||
China | 12 | 1209 | 2.793 (2.310–3.376) | 0.000 | 0.0%, 0.924 | |
Other | 3 | 660 | 1.164 (0.577–2.346) | 0.672 | 83.5%, 0.002 | |
Cancer type | ||||||
Estrogen-dependent carcinoma | 2 | 198 | 3.296 (2.027–5.358) | 0.000 | 22.9%, 0.255 | |
Urological carcinoma | 2 | 226 | 3.184 (2.072–4.892) | 0.000 | 0.0%, 0.739 | |
Glioma | 2 | 258 | 2.750 (1.839–4.111) | 0.000 | 0.0%, 0.553 | |
Digestive carcinoma | 6 | 633 | 1.750 (0.974–3.143) | 0.061 | 79.7%, 0.000 | |
Other | 3 | 554 | 2.154 (1.471–3.154) | 0.000 | 0.0%, 0.484 | |
Sample size | ||||||
Sample < 100 | 5 | 333 | 2.443 (1.655–3.608) | 0.000 | 0.0%, 0.752 | |
Sample > 100 | 10 | 1536 | 2.203 (1.516–3.202 | 0.000 | 77.9%, 0.000 | |
Multivariate | Overall | 18 | 1891 | 2.298 (1.953–2.704) | 0.000 | 17.2%, 0.248 |
Region | ||||||
China | 17 | 1817 | 2.327 (1.968–2.751) | 0.000 | 20.6%, 0.213 | |
Other | 1 | 74 | 1.880 (0.957–3.695) | 0.067 | – | |
Cancer type | ||||||
Estrogen-dependent carcinoma | 2 | 198 | 2.656 (1.560–4.523) | 0.000 | 0.0%, 0.457 | |
Urological carcinoma | 3 | 321 | 1.952 (1.189–3.204) | 0.008 | 51.4%, 0.128 | |
Glioma | 4 | 430 | 2.315 (1.643–3.263) | 0.000 | 0.0%, 0.534 | |
Digestive carcinoma | 7 | 706 | 2.451 (1.862–3.227) | 0.000 | 45.4%, 0.089 | |
Other | 2 | 236 | 2.383 (1.449–3.920) | 0.001 | 3.3%, 0.309 | |
Sample size | ||||||
Sample < 100 | 7 | 528 | 2.017 (1.520–2.677) | 0.000 | 10.4%, 0.350 | |
Sample > 100 | 11 | 1363 | 2.451 (2.009–2.990) | 0.000 | 20.7%, 0.246 |
Survival outcome | Survival analysis | Studies (n) | Patients (n) | HR (95% CI) | P | Heterogeneity (I2, P value) |
---|---|---|---|---|---|---|
RFS | Univariate | 5 | 397 | 1.355 (0.751–2.445) | 0.313 | 70.6%, 0.009 |
Multivariate | 3 | 263 | 2.491 (1.505–4.123) | 0.000 | 0.0%, 0.435 | |
DFS | Univariate | 1 | 77 | 1.820 (1.018–3.255) | 0.044 | – |
Multivariate | 3 | 329 | 2.036 (1.240–3.342) | 0.005 | 32.7%, 0.226 | |
DSS | Univariate | 3 | 2037 | 1.791 (1.304–2.459) | 0.000 | 4.5%, 0.351 |
Multivariate | 3 | 2037 | 2.098 (1.372–3.211) | 0.001 | 0.0%, 0.578 | |
PFS | Univariate | 1 | 100 | 3.03 (1.578–5.820) | 0.001 | – |
Multivariate | 2 | 175 | 1.842 (1.138–2.983) | 0.013 | 0.0%, 0.940 |
Publication bias and sensitivity analysis
Carcinogenic mechanisms of MALAT1 among various cancers
Cancer type | Expression effect | Transition of cell phenotype of MALAT1 silencing | Molecular mechanisms | References |
---|---|---|---|---|
Breast cancer | Up-regulated | G0/G1 phase cell cycle arrest; ↓ proliferation/migration/invasion | MALAT1 influenced cells progression by miR-129-5p; MALAT1 functions as a ceRNA of cdc42 in inducing EMT by binding miR-1 competitively | |
Gallbladder cancer | Up-regulated | ↓ Proliferation and metastasis | MALAT1 activates the ERK/MAPK pathway | [70] |
Colorectal cancer | Up-regulated | ↓ Proliferation/migration/invasion | Knockdown of AKAP-9 blocks MALAT1-mediated proliferation, migration and invasion; MALAT1 might bind to SFPQ, therefore releasing PTBP2 from the SFPQ/PTBP2 complex; SFPQ regulated the effect of MALAT1 on cell proliferation and migration | |
Osteosarcoma | Up-regulated | ↓ Invasion/proliferation/metastasis | MALAT1 knockdown inhabits PI3K/Akt pathways | [62] |
Lung cancer | Up-regulated | ↓ Migration/growth/invasion | MALAT1 regulates by TDP-43; MALAT1 silencing reduces the expression of CXCL5; the promoter methylation regulates MALAT1 expression; MALAT1 up-regulated the expression of miR-204 target gene SLUG through competitively ‘sponging’ miR-204 | |
Pancreatic cancer | Up-regulated | G2/M cell cycle arrest; ↑ apoptosis; ↓ proliferation/metastasis/migration/invasion | MALAT1 promotes proliferation and metastasis by the stimulation of autophagy and inducing EMT | |
Cervical cancer | Up-regulated | ↓ Invasion/metastasis; ↑ apoptosis | MALAT1 regulates EMT by up-regulating transcriptional factor Snail | |
Gastric cancer | Up-regulated | ↓ Proliferation/migration/invasion/metastasis | MALAT1 regulates via increasing EGFL7 expression; MALAT1 regulates VE-cadherin/β-catenin complex, ERK/MMP and FAX/paxillin singling pathways involved in VM formation and angiogenesis; MALAT1 regulates miR-1297 to modulate HMGB2 | |
Esophageal squamous cell carcinoma | Up-regulated | ↓ Proliferation/migration/invasion/metastasis; ↑ apoptosis; G2/M phase cell cycle arrest | MALAT1 regulates the expression of β-catenin and Lin28 via Ezh2; Silencing of MALAT1 caused by miR-101 and miR-217; Knockdown of MALAT1 induces cell cycle arrest by activating the ATM-CHK2 pathway | |
Hepatocellular carcinoma | Up-regulated | ↓ Proliferation/invasion | MALAT1 regulates ZEB1 expression by sponging miR-143-3p | [14] |
Renal cell carcinoma | Up-regulated | ↓ Proliferation/invasion; ↑ apoptosis | Knockdown of MALAT1 significantly increases miR-205 expression in renal cancer cells; MALAT1 silencing elevated E-cadherin expression, whereas b-catenin expression reduced through Ezh2 to block EMT | [33] |
Mantle cell lymphoma | Up-regulated | ↓ Proliferation; ↑ apoptosis; S/G1 phase cell cycle arrest | MALAT1 represses the expression of PRC2-dependent target genes by ineracting with EZH2 | [48] |
Prostate cancer | Up-regulated | ↓ Growth/invasion/migration; G0/G1 phase cell cycle arrest | MALAT1 increases oncogenic activities of EZH2 | |
Pancreatic ductal adenocarcinoma | Up-regulated | ↓ Proliferation/migration/invasion/growth and cell cycle progression; ↑ apoptosis | MALAT1 acts as a ceRNA to regulate KRAS expression by sponging miR-217 | [72] |
Bladder cancer | Up-regulated | ↓ Migration and metastasis | MALAT1 regulates TGF-b-induced EMT; MALAT1 promotes EMT by activating the Wnt/β-catenin signaling pathway | |
Epithelial ovarian cancer | Up-regulated | ↓ Proliferation/invasion/metastasis; ↑ apoptosis | MALAT1 induces EMT via PI3K/AKT pathway | [71] |
Glioma | Down-regulated | ↑ Proliferation/viability/progression | MALAT1 suppresses miR-155 expression and activates FBXW7 function | [52] |